Endocrine Interplay in Metabolic Syndrome

TheEndocrine interplay in metabolic syndrome intricate interplay of endocrine factors in metabolic syndrome (MetS) orchestrates a complex network of hormonal and metabolic processes. MetS manifests as a constellation of metabolic abnormalities, including insulin resistance, atherogenicAtherogenic dyslipidemiaAtherogenic dyslipidemia, central obesity, and hypertension. These disturbances arise from a combination of genetic predispositions and acquired lifestyle factors, underscoring the multifactorial nature of MetS pathogenesisMetabolic syndromepathogenesis. Among the key players in this interplay is adipose tissue, which operates as an endocrine organ, secreting a myriad of hormones and cytokines known as adipokines. Dysregulated secretion of adipokines, such as adiponectinAdipokinesadiponectin and leptinLeptin, contributes to the development of insulin resistance and chronic low-grade inflammation, exacerbating metabolic dysfunction in MetS. Additionally, other endocrine factors, including cortisolCortisol, thyroid hormones, and the renin–angiotensin–aldosterone systemRenin-angiotensin-aldosterone system, interact synergistically to influence glucose and lipid metabolismLipid metabolism, blood pressure regulation, and adipose tissue function. Imbalances in these hormonal axes further fuel the progression of MetS and its associated complications.Understanding the intricate interplay among these endocrine factors is paramount for effective management and prevention of MetS. Targeted interventions aimed at modulating hormonal pathways, such as lifestyle modificationsRole of SIDDHA in Metabolic syndromelifestyle modifications, pharmacotherapy, and emerging therapies targeting adipose tissue inflammation and insulin resistance, hold promise in mitigating the metabolic derangements underlying MetS.